{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:21:13Z","timestamp":1790310073005,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Andre Maaske and Rebecca He\u03b2"},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["RTG1949\/1"],"award-info":[{"award-number":["RTG1949\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.vaccine.2018.02.075","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T01:30:25Z","timestamp":1522978225000},"page":"2712-2720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses"],"prefix":"10.1016","volume":"36","author":[{"given":"Dennis","family":"Lapuente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Ruzsics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thirion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Tenbusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.02.075_b0005","unstructured":"Human Adenovirus Working Group Human Adenovirus Genotype Classification n.d. http:\/\/hadvwg.gmu.edu\/ [accessed August 2, 2017]."},{"key":"10.1016\/j.vaccine.2018.02.075_b0010","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1542\/peds.113.1.e51","article-title":"Adenoviral infections in children: the impact of rapid diagnosis","volume":"113","author":"Rocholl","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.02.075_b0015","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1073\/pnas.95.5.2509","article-title":"A simplified system for generating recombinant adenoviruses","volume":"95","author":"He","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2018.02.075_b0020","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1016\/j.vaccine.2007.07.035","article-title":"Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein","volume":"25","author":"Roy","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.075_b0025","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"Quinn","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2018.02.075_b0030","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1473-3099(11)70240-7","article-title":"DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials","volume":"11","author":"Ledgerwood","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.075_b0035","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/viro.1996.0239","article-title":"A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier","volume":"219","author":"Xiang","year":"1996","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.02.075_b0040","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1016\/j.vaccine.2005.04.047","article-title":"Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein","volume":"23","author":"Epstein","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.075_b0045","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1038\/mt.2010.202","article-title":"A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge","volume":"18","author":"Zhou","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2018.02.075_b0050","doi-asserted-by":"crossref","first-page":"12601","DOI":"10.1128\/JVI.01036-09","article-title":"Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized f protein of respiratory syncytial virus","volume":"83","author":"Kohlmann","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.075_b0055","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.vaccine.2004.07.043","article-title":"Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans","volume":"23","author":"Van Kampen","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.075_b0060","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.02.075_b0065","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.vaccine.2010.10.037","article-title":"A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults","volume":"29","author":"Ledgerwood","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.075_b0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006843","article-title":"A Human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"Smaill","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2018.02.075_b0075","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.4161\/hv.24941","article-title":"Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection","volume":"9","author":"Tamminga","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.02.075_b0080","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.075_b0085","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4049\/jimmunol.170.3.1416","article-title":"A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag","volume":"170","author":"Fitzgerald","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.02.075_b0090","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/JVI.77.11.6305-6313.2003","article-title":"Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene","volume":"77","author":"Casimiro","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.075_b0095","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1128\/JVI.77.16.8729-8735.2003","article-title":"Plasmid Chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines","volume":"77","author":"Barouch","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.075_b0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/aid.2008.0212","article-title":"Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults","volume":"25","author":"Harro","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2018.02.075_b0105","doi-asserted-by":"crossref","first-page":"8100","DOI":"10.1128\/JVI.00687-06","article-title":"Transposon-assisted cloning and traceless mutagenesis of adenoviruses: Development of a novel vector based on species D","volume":"80","author":"Ruzsics","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.075_b0110","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/hum.2006.17.193","article-title":"Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy","volume":"17","author":"Thirion","year":"2006","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2018.02.075_b0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004397-200201000-00008","article-title":"A twenty-one year surveillance of adenoviral conjunctivitis in Sapporo, Japan","volume":"42","author":"Aoki","year":"2002","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.vaccine.2018.02.075_b0120","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.075_b0125","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1167\/iovs.12-9656","article-title":"Analysis of human adenovirus type 19 associated with epidemic keratoconjunctivitis and its reclassification as adenovirus type 64","volume":"53","author":"Zhou","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.vaccine.2018.02.075_b0130","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.4049\/jimmunol.173.3.1978","article-title":"Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract","volume":"173","author":"Renegar","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.02.075_b0135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1189\/jlb.0313180","article-title":"Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection","volume":"95","author":"Wu","year":"2014","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.vaccine.2018.02.075_b0140","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85832","article-title":"Vaccine-generated lung tissue\u2013resident memory T cells provide heterosubtypic protection to influenza infection","volume":"1","author":"Zens","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2018.02.075_b0145","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1016\/j.vaccine.2010.02.090","article-title":"Codon-optimization of the hemagglutinin gene from the novel swine origin H1N1 influenza virus has differential effects on CD4+ T-cell responses and immune effector mechanisms following DNA electroporation in mice","volume":"28","author":"Tenbusch","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.075_b0150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2016.06.043","article-title":"Mucosal expression of DEC-205 targeted allergen alleviates an asthmatic phenotype in mice","volume":"237","author":"Maaske","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2018.02.075_b0155","doi-asserted-by":"crossref","first-page":"e72217","DOI":"10.1371\/journal.pone.0072217","article-title":"Protective efficacy and immunogenicity of a combinatory DNA vaccine against influenza A virus and the respiratory syncytial virus","volume":"8","author":"Stab","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.02.075_b0160","doi-asserted-by":"crossref","first-page":"e13162","DOI":"10.1371\/journal.pone.0013162","article-title":"Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses","volume":"5","author":"Price","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.02.075_b0165","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1016\/j.vaccine.2011.07.093","article-title":"Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses","volume":"29","author":"Lanthier","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.075_b0170","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","article-title":"Integrins \u03b1v\u03b23 and \u03b1v\u03b25 promote adenovirus internalization but not virus attachment","volume":"73","author":"Wickham","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2018.02.075_b0175","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2018.02.075_b0180","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1073\/pnas.94.7.3352","article-title":"HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses","volume":"94","author":"Tomko","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2018.02.075_b0185","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.yexcr.2006.01.025","article-title":"The coxsackie- and adenovirus receptor (CAR) is an in vivo marker for epithelial tight junctions, with a potential role in regulating permeability and tissue homeostasis","volume":"312","author":"Raschperger","year":"2006","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.vaccine.2018.02.075_b0190","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1099\/vir.0.008342-0","article-title":"Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN","volume":"90","author":"Adams","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.02.075_b0195","doi-asserted-by":"crossref","first-page":"7691","DOI":"10.1128\/JVI.74.16.7691-7693.2000","article-title":"Initial interactions of subgenus D adenoviruses with a549 cellular receptors: sialic acid versus alpha v integrins","volume":"74","author":"Arnberg","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.075_b0200","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.virol.2004.04.001","article-title":"Adenovirus type 5 pseudotyped with adenovirus type 37 fiber uses sialic acid as a cellular receptor","volume":"324","author":"Cashman","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.02.075_b0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00491","article-title":"Dendritic cells: a spot on sialic acid","volume":"4","author":"Crespo","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.02.075_b0210","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/BF02976990","article-title":"Airway mucus: its components and function","volume":"25","author":"Lillehoj","year":"2002","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.vaccine.2018.02.075_b0215","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI0215217","article-title":"Mucus clearance as a primary innate defense mechanism for mammalian airways","volume":"109","author":"Knowles","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2018.02.075_b0220","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/1743-422X-10-321","article-title":"Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase","volume":"10","author":"Cohen","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2018.02.075_b0225","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1128\/JVI.78.8.3897-3905.2004","article-title":"Membrane cofactor protein is a receptor for adenoviruses associated with epidemic keratoconjunctivitis","volume":"78","author":"Wu","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.075_b0230","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1006\/viro.1996.8269","article-title":"Fiber genes of adenoviruses with tropism for the eye and the genital tract","volume":"227","author":"Arnberg","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.02.075_b0235","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s007050050071","article-title":"Conserved sequences in the fibers of epidemic keratoconjunctivitis associated human adenoviruses","volume":"142","author":"Pring-\u00c5kerblom","year":"1997","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2018.02.075_b0240","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1128\/MCB.23.7.2614-2622.2003","article-title":"Disruption of mouse CD46 causes an accelerated spontaneous acrosome reaction in sperm","volume":"23","author":"Inoue","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.vaccine.2018.02.075_b0245","first-page":"341","article-title":"Identification and quantification of complement regulator CD46 on normal human tissues","volume":"79","author":"Johnstone","year":"1993","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2018.02.075_b0250","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1099\/vir.0.81293-0","article-title":"Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors","volume":"87","author":"Verhaagh","year":"2006","journal-title":"J Gen Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18302627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18302627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T13:28:56Z","timestamp":1534944536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18302627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":50,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0264410X18302627"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.075","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}